OMEROS CORP Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Omeros Corporation on November 9, 2022. The report serves to announce the company's financial results for the three and nine months ended September 30, 2022. The specific financial data is contained within a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced press release (Exhibit 99.1) rather than the body of this 8-K form.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. Investors must refer to the attached press release for comparative analysis of the three and nine-month periods ended September 30, 2022.
Guidance, Outlook, and Risks
The text does not include specific guidance, management commentary, or risk factors. The filing includes a standard disclaimer stating that the information in this report and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings.
Key Facts for Investor Verification
- Verify the specific revenue and net loss figures in the press release (Exhibit 99.1) for the three and nine months ended September 30, 2022.
- Confirm the company's cash position and burn rate as detailed in the referenced exhibit.
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are typical drivers for Omeros Corporation.
- Note that this 8-K is a notification of results and does not contain the granular financial data itself.